A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases

Grant

Date/time Interval

  • November 6, 2012 - November 5, 2017

    • Awarded By

    Total Award Amount

  • 43500.00

    • Direct Costs

  • 34524.00

    • Sponsor Award Id

    • Contributor

  • Nabell M.D., Lisle   Principal Investigator